These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 10671334

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J.
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M, CNA2007 International Study Team.
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [Abstract] [Full Text] [Related]

  • 5. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron JJ, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R, Masur H, CNA2007 Study Team.
    AIDS; 2002 Feb 15; 16(3):387-96. PubMed ID: 11834950
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S, Yeni PG, Bouchaud O, Costagliola D, Clinical Epidemiology Group of the French Hospital Database on HIV.
    Clin Infect Dis; 2007 Jan 01; 44(1):120-7. PubMed ID: 17143827
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
    Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S.
    HIV Med; 2005 May 01; 6(3):179-84. PubMed ID: 15876284
    [Abstract] [Full Text] [Related]

  • 10. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L, EuroSIDA Study Group.
    Antivir Ther; 2004 Oct 01; 9(5):787-800. PubMed ID: 15535417
    [Abstract] [Full Text] [Related]

  • 11. Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
    Goujard C, Vincent I, Meynard JL, Choudet N, Bollens D, Rousseau C, Demarles D, Gillotin C, Bidault R, Taburet AM.
    Antimicrob Agents Chemother; 2003 Jan 01; 47(1):118-23. PubMed ID: 12499178
    [Abstract] [Full Text] [Related]

  • 12. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
    Funk MB, Notheis G, Schuster T, Elanjkal Z, von Hentig N, Stürmer M, Linde R, Dunsch D, Königs C, Wintergerst U, Kreuz W.
    Eur J Med Res; 2005 Dec 07; 10(12):503-8. PubMed ID: 16356864
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD, Adult AIDS Clinical Trials Group Protocol 368/886 Study Team.
    Antimicrob Agents Chemother; 2003 Jun 07; 47(6):1929-35. PubMed ID: 12760869
    [Abstract] [Full Text] [Related]

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 07; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 17. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus.
    Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chêne G, Clavel F, Girard PM.
    Clin Pharmacol Ther; 2004 Apr 07; 75(4):310-23. PubMed ID: 15060509
    [Abstract] [Full Text] [Related]

  • 18. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D, Lederman M, Haas DW, Haubrich R, Stanford J, Cooney E, Horton J, Kelleher D, Ross L, Cutrell A, Lee D, Spreen W, Mellors JW.
    Antivir Ther; 2001 Jun 07; 6(2):105-14. PubMed ID: 11491415
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.